Improvements in Lung Function Outcomes in Children with Cystic Fibrosis are Associated with Better Nutrition, Fewer Chronic Pseudomonas aeruginosa Infections, and Dornase Alfa Use - 07/03/14
, James D. Acton, MD, Matthew C. Fenchel, MS, Raouf S. Amin, MD, Michael Seid, PhD
Reprint requests: Gary L. McPhail, MD, Division of Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, ML 2021, 3333 Burnet Avenue, Cincinnati, OH 45229-3039Résumé |
Objective |
To compare lung function and nutritional outcomes in cystic fibrosis (CF) for 2 birth cohorts in our CF center.
Study design |
Patients with CF born between 1985 and 2000 treated in our CF center before age 5 years were included. The patients were divided into 2 equal birth cohorts for comparison: birth cohort 1 (born between 1985 and 1992) and birth cohort 2 (born between 1993 and 2000). To compare lung function, we used forced expiratory volume in the first second (FEV1)% predicted and FEV1% predicted slope from age 6 to 12 years. We hypothesized that we would find significant improvements in lung function and nutritional outcomes in our patients with CF.
Results |
The patients born between 1993 and 2000 (birth cohort 2) had better lung function, a slower rate of decline in lung function, and better nutritional outcomes compared with those born between 1985 and 1992 (birth cohort 1). Factors associated with a slower rate of decline in lung function in both groups were a higher baseline body mass index (BMI)%, a slower BMI% rate of decline, absence of chronic Pseudomonas aeruginosa respiratory infection, and initiation of dornase alfa (Pulmozyme) therapy before age 9 years.
Conclusion |
Our results demonstrate dramatically improved lung function and nutritional outcomes in the children with CF in our center. The improvements in lung function outcomes are associated with better nutrition, fewer chronic P aeruginosa infections, and dornase alfa therapy.
Le texte complet de cet article est disponible en PDF.Abbreviations : BMI, BMI%, CF, FEV1, Height-for-age%, Weight-for-age%
Plan
| The authors have no conflicts of interest to disclose. There was no sponsor involvement in the design of this study or in the preparation of this manuscript for publication. |
Vol 153 - N° 6
P. 752-757 - décembre 2008 Retour au numéro
Article précédent
- Relationship between Inhaled Corticosteroid Therapy and Rate of Lung Function Decline in Children with Cystic Fibrosis
- Clement L. Ren, David J. Pasta, Lawrence Rasouliyan, Jeffrey S. Wagener, Michael W. Konstan, Wayne J. Morgan, Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis ⁎
- 50 Years Ago in The Journal of Pediatrics : Empyema in children: A 25-year study
- Adam Jaffé
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?